Marcus' research interests are primarily involved in the extensive assessment of clinical trial evidence as well as economic and epidemiological models. This research culminates in the submission of independent written evaluations (commentaries) for consideration by the Pharmaceutical Benefits Advisory Committee (PBAC), which is responsible for making recommendations for the listing of drugs on the pharmaceutical benefits scheme (PBS). In addition, Marcus has recently been involved in research regarding the economic evaluation of targetted oncology therapies.
Marcus Tan's teaching responsibilities involve:
- Health Technology Assessment 1 (HTA1) - commencing trimester 2, 2015 - unit coordinator
- Supervisor for one master's student